Today: 8 June 2026
Browse Category

NASDAQ:CAVA 6 December 2025 - 20 May 2026

CAVA Jumps in Pre-Market After New Traffic Data Update

CAVA Jumps in Pre-Market After New Traffic Data Update

Cava Group shares rose 6.9% in premarket trading Wednesday after the chain reported a 9.7% jump in same-restaurant sales and beat first-quarter earnings and revenue estimates. Net income fell to $23.6 million from $25.7 million a year earlier. The company opened 20 net new restaurants and raised its 2026 outlook for openings and sales growth. Several analysts raised their price targets following the results.
20 May 2026
··
Cava Earnings Beat Challenges Restaurant Slowdown Talk

Cava Earnings Beat Challenges Restaurant Slowdown Talk

Cava raised its 2026 sales and profit outlook after first-quarter same-restaurant sales jumped 9.7%, driven mostly by a 6.8% rise in guest traffic. Revenue reached $438.3 million, topping analyst estimates, while net income slipped to $23.6 million from $25.7 million a year earlier. Shares rose 6% after hours. The company now expects same-restaurant sales growth of 4.5% to 6.5% for the year.
19 May 2026
···
CAVA Group Inc (CAVA) Stock Outlook 2026: Institutional Buying, Q3 Reset and Analyst Price Target Forecasts

CAVA Group Inc (CAVA) Stock Outlook 2026: Institutional Buying, Q3 Reset and Analyst Price Target Forecasts

CAVA shares closed December 5 at just over $53, down more than 60% from their 52-week high of $151. Norges Bank disclosed a $56 million stake, while Baird Financial Group and New York State Common Retirement Fund also sharply increased holdings. About 73% of CAVA’s float is now held by institutions. Insider Kenneth Robert Bertram sold 3,788 shares but retains over 51,000.
6 December 2025
··

Stock Market Today

  • Cenovus Energy Analyst Price Targets Remain Steady Amid Unchanged Valuations
    June 8, 2026, 10:04 AM EDT. Cenovus Energy (TSX:CVE) saw no changes in analyst price targets or valuation assumptions in the latest update, reflecting stable revenue growth, net profit margins, and price-to-earnings (P/E) ratios. The company's investment outlook remains linked to its operational plans and commodity market exposure, with key risks including execution challenges and financial resilience. Investors are encouraged to monitor ongoing narratives and potential catalysts through community insights, as no new financial data or adjustments have emerged. This steadiness underscores a cautious yet stable investment stance on Cenovus amid evolving market conditions.

Latest articles

Corning Wins Amazon AI Fiber Deal; GLW Faces Next Hurdle

Corning Wins Amazon AI Fiber Deal; GLW Faces Next Hurdle

8 June 2026
Amazon’s new multibillion-dollar supply deal makes Corning a key fiber provider for U.S. data centers, but with shares up 305% in 12 months and investors already pricing in big AI wins, the stock was little changed at $177.58 premarket as risks of factory delays and high expectations loom.
BlackBerry Shares Stall After QNX Push

BlackBerry Stock Moves in Pre-Market Ahead of June Test

8 June 2026
BlackBerry’s U.S. shares rose 2.34% in premarket trading to $9.63 after Friday’s 8.99% drop, but with analyst targets averaging just $4.98, investors are betting on QNX growth and secure-communications wins ahead of June 25 earnings; any disappointment could hit the stock hard.
Micron Technology Stock Surges as AI Memory Shortage Puts MU at Center of Chip Rally

Micron Shares Edge Up in Premarket; Investors Await Next AI Test

8 June 2026
Micron surged 8.2% to $935.07 in Nasdaq premarket after Friday’s $127 billion rout, as investors cheered Nvidia’s confirmation it will keep sourcing high-bandwidth memory from Micron and Samsung, easing fears SK Hynix would become exclusive supplier; Cantor Fitzgerald raised its price target to $1,500, with Micron’s next earnings report due June 24.
Tango Therapeutics Stock Surges After Cancer Drug Shows 92% Response Rate

Tango Therapeutics Stock Surges After Cancer Drug Shows 92% Response Rate

8 June 2026
Tango shares soared up to 48% in premarket trading after reporting a 92% objective response rate and 90% six-month progression-free survival in a 12-patient pancreatic cancer trial, with plans to advance the vopimetostat-daraxonrasib combo to Phase 3 testing in first-line MTAP-deleted pancreatic cancer.
Go toTop